Article Correctness Is Author's Responsibility: MD Anderson Cancer Center and Pfizer Oncology Announce Clinical Collaboration to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors

The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
Posted in Uncategorized